IMRN – Immuron Limited ADR
Immuron LimitedIMRN
$0.9Name : Immuron Limited
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $7,264,081.00
EPSttm : -0.34
Immuron Limited
$0.9
2.27%$0.02
IMRN — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
2.04
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
EPS Last/This Y
0.33
EPS This/Next Y
Price
0.9
Target Price
2.65
Analyst Recom
2
Performance Q
-19.13
Upside
-596.6%
Beta
1.19
Ticker: IMRN
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-10-12 | IMRN | 1.05 | N/A | N/A | 0 |
| 2026-10-13 | IMRN | 1.04 | N/A | N/A | 0 |
| 2026-10-14 | IMRN | 1.01 | N/A | N/A | 0 |
| 2026-10-15 | IMRN | 1.0299 | N/A | N/A | 0 |
| 2026-10-16 | IMRN | 0.98 | N/A | N/A | 0 |
| 2026-10-19 | IMRN | 0.9598 | N/A | N/A | 0 |
| 2026-10-20 | IMRN | 1.01 | N/A | N/A | 0 |
| 2026-10-21 | IMRN | 0.9885 | N/A | N/A | 0 |
| 2026-10-22 | IMRN | 0.9443 | N/A | N/A | 0 |
| 2026-10-23 | IMRN | 0.9601 | N/A | N/A | 0 |
| 2026-10-26 | IMRN | 0.93 | N/A | N/A | 0 |
| 2026-10-27 | IMRN | 0.9374 | N/A | N/A | 0 |
| 2026-10-28 | IMRN | 0.9176 | N/A | N/A | 0 |
| 2026-10-29 | IMRN | 0.9225 | N/A | N/A | 0 |
| 2026-10-30 | IMRN | 0.88 | N/A | N/A | 0 |
| 2026-11-02 | IMRN | 0.8977 | N/A | N/A | 0 |
| 2026-11-03 | IMRN | 0.8699 | N/A | N/A | 0 |
| 2026-11-04 | IMRN | 0.8529 | N/A | N/A | 0 |
| 2026-11-05 | IMRN | 0.8499 | N/A | N/A | 0 |
| 2026-11-06 | IMRN | 0.8187 | N/A | N/A | 0 |
| 2026-11-09 | IMRN | 0.8601 | N/A | N/A | 0 |
| 2026-11-10 | IMRN | 0.9 | N/A | N/A | 0 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-10-12 | IMRN | 1.04 | - | - | -0.02 |
| 2026-10-13 | IMRN | 1.03 | - | - | -0.02 |
| 2026-10-14 | IMRN | 1.01 | - | - | -0.02 |
| 2026-10-15 | IMRN | 1.03 | - | - | -0.02 |
| 2026-10-16 | IMRN | 0.96 | - | - | -0.02 |
| 2026-10-19 | IMRN | 0.96 | - | - | -0.02 |
| 2026-10-20 | IMRN | 0.96 | - | - | -0.02 |
| 2026-10-21 | IMRN | 1.01 | - | - | -0.02 |
| 2026-10-22 | IMRN | 0.97 | - | - | -0.02 |
| 2026-10-23 | IMRN | 0.95 | - | - | -0.02 |
| 2026-10-26 | IMRN | 0.98 | - | - | -0.02 |
| 2026-10-27 | IMRN | 0.94 | - | - | -0.02 |
| 2026-10-28 | IMRN | 0.92 | - | - | -0.02 |
| 2026-10-29 | IMRN | 0.90 | - | - | -0.02 |
| 2026-10-30 | IMRN | 0.88 | - | - | -0.02 |
| 2026-11-02 | IMRN | 0.90 | - | - | -0.02 |
| 2026-11-03 | IMRN | 0.88 | - | - | -0.02 |
| 2026-11-04 | IMRN | 0.85 | - | - | -0.02 |
| 2026-11-05 | IMRN | 0.85 | - | - | -0.02 |
| 2026-11-06 | IMRN | 0.85 | - | - | -0.02 |
| 2026-11-09 | IMRN | 0.89 | - | - | -0.02 |
| 2026-11-10 | IMRN | 0.90 | - | - | -0.02 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-10-12 | IMRN | 0 | 10.38 | 1.90 |
| 2026-10-13 | IMRN | 0 | 10.38 | 1.90 |
| 2026-10-14 | IMRN | 0 | 10.38 | 1.90 |
| 2026-10-15 | IMRN | 0 | 10.38 | 1.90 |
| 2026-10-16 | IMRN | 0 | 10.38 | 1.90 |
| 2026-10-19 | IMRN | 0 | 10.38 | 1.90 |
| 2026-10-20 | IMRN | 0 | 10.38 | 1.90 |
| 2026-10-21 | IMRN | 0 | 10.38 | 1.90 |
| 2026-10-22 | IMRN | 0 | 10.38 | 1.90 |
| 2026-10-23 | IMRN | 0 | 10.38 | 1.90 |
| 2026-10-26 | IMRN | 0 | 10.38 | 1.90 |
| 2026-10-27 | IMRN | 0 | 10.38 | 2.04 |
| 2026-10-28 | IMRN | 0 | 10.38 | 2.04 |
| 2026-10-29 | IMRN | 0 | 10.38 | 2.04 |
| 2026-10-30 | IMRN | 0 | 10.38 | 2.04 |
| 2026-11-02 | IMRN | 0 | 10.38 | 2.04 |
| 2026-11-03 | IMRN | 0 | 10.38 | 2.04 |
| 2026-11-05 | IMRN | 0 | 10.38 | 2.04 |
| 2026-11-06 | IMRN | 0 | 10.38 | 2.04 |
| 2026-11-09 | IMRN | 0 | 10.38 | 2.04 |
| 2026-11-10 | IMRN | 0 | 10.38 | 2.04 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
Avg. EPS Est. Next Quarter
Insider Transactions
Institutional Transactions
10.38
Beta
1.19
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
49
Growth Score
40
Sentiment Score
87
Actual DrawDown %
84.9
Max Drawdown 5-Year %
-84.6
Target Price
2.65
P/E
Forward P/E
PEG
P/S
1.38
P/B
0.93
P/Free Cash Flow
EPS
-0.34
Average EPS Est. Cur. Y
-0.02
EPS Next Y. (Est.)
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-47.78
Relative Volume
Return on Equity vs Sector %
-59.3
Return on Equity vs Industry %
-39.5
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
◆
IMRN
Healthcare
$0.89
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
40
Range 1M
37.5%
Sup Dist
6.2%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
98.2%
EPS NY
0%
52W%
17%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+197.8% upside
Upside
+197.8%
Quality
49
IMRN — P/E HistoricalBiotechnology
Immuron LimitedSector: Healthcare
Industry: Biotechnology
Employees: 7
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; ProIBS, an over the counter orally administered product containing the proprietary ingredient AVH200 for the treatment of irritable bowel syndrome; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. It also develops IMM-529, which is in Phase II clinical trial for the treatment of Clostridioides difficile infection. In addition, the company offers technology platform. The company has a collaboration with the US Naval Medical Research Command and Silver Spring, MD, USA; and a research collaboration with the Walter Reed Army Institute of Research to develop three Shigella-specific therapeutic products. The company was formerly known as Anadis Limited and changed its name to Immuron Limited in December 2008. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.
IMRN
Latest News
—
Caricamento notizie per IMRN…
stock quote shares IMRN – Immuron Limited ADR Stock Price stock today
news today IMRN – Immuron Limited ADR stock forecast ,stock prediction 2023 2024 2025
marketwatch IMRN – Immuron Limited ADR yahoo finance google finance
stock history IMRN – Immuron Limited ADR invest stock market
stock prices IMRN premarket after hours
ticker IMRN fair value insiders trading